Renaissance Technologies
MRVI icon

Renaissance Technologies’s Maravai LifeSciences MRVI Stock Holding History

Renaissance Technologies’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.7M Buy
4,606,491
+341,802
+8% +$1.48M 0.04% 553
2026
Q1 		$12.1M Buy
4,264,689
+39,600
+0.9% +$134K 0.02% 878
2025
Q4 		$13.7M Sell
4,225,089
-93,000
-2% -$313K 0.02% 771
2025
Q3 		$12.4M Buy
4,318,089
+131,900
+3% +$337K 0.02% 981
2025
Q2 		$10.1M Buy
4,186,189
+75,500
+2% +$159K 0.01% 1052
2025
Q1 		$9.08M Buy
4,110,689
+138,500
+3% +$547K 0.01% 1053
2024
Q4 		$21.6M Sell
3,972,189
-166,286
-4% -$1.07M 0.03% 637
2024
Q3 		$34.4M Buy
4,138,475
+257,034
+7% +$2.22M 0.05% 450
2024
Q2 		$27.8M Buy
3,881,441
+668,552
+21% +$5.77M 0.05% 470
2024
Q1 		$27.9M Buy
3,212,889
+327,200
+11% +$2.21M 0.04% 496
2023
Q4 		$18.9M Buy
2,885,689
+226,000
+8% +$1.46M 0.03% 637
2023
Q3 		$26.6M Buy
2,659,689
+218,514
+9% +$2.4M 0.05% 454
2023
Q2 		$30.3M Sell
2,441,175
-751,325
-24% -$10.1M 0.04% 487
2023
Q1 		$44.7M Sell
3,192,500
-134,448
-4% -$1.93M 0.06% 385
2022
Q4 		$47.6M Buy
3,326,948
+1,804,248
+118% +$28.4M 0.07% 351
2022
Q3 		$38.9M Sell
1,522,700
-352,300
-19% -$8.84M 0.06% 396
2022
Q2 		$53.3M Buy
1,875,000
+961,800
+105% +$30.5M 0.06% 346
2022
Q1 		$32.2M Buy
913,200
+368,400
+68% +$12.3M 0.04% 513
2021
Q4 		$22.8M Sell
544,800
-405,281
-43% -$16.4M 0.03% 641
2021
Q3 		$46.6M Buy
950,081
+305,281
+47% +$14.9M 0.06% 327
2021
Q2 		$26.9M Buy
+644,800
New +$25M 0.03% 584

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies's MRVI Position: Q2 2026 in Review

Renaissance Technologies increased its Maravai LifeSciences (MRVI) stake by 8% in Q2 2026, buying an estimated $1.48M and bringing the position to 4,606,491 shares worth $28.7M. The position accounts for 0.04% of the portfolio, ranked #553.

Renaissance Technologies first reported a position in MRVI in Q2 2021 and has held it in 21 quarters since. The position peaked at $53.3M in Q2 2022. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Renaissance Technologies held 4,606,491 shares of Maravai LifeSciences worth $28.7M as of Q2 2026.
  • Renaissance Technologies bought 341,802 Maravai LifeSciences shares in Q2 2026, an estimated $1.48M.
  • Maravai LifeSciences made up 0.04% of Renaissance Technologies's portfolio in Q2 2026, its #553 holding.
  • Renaissance Technologies first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 21 quarters since.
  • Renaissance Technologies's Maravai LifeSciences position peaked at $53.3M in Q2 2022.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.